Lakshmikumaran & Sridharan advised LifeCell International, a stem cell bank and reproductive genetic testing services provider, in its recent fundraise of ₹2.25 billion (USD 29.8 million) from life sciences investment firm OrbiMed Asia. IndusLaw represented OrbiMed Asia.
Announcing the deal on 22 September, LifeCell International said its existing founders would be investing ₹300 million as part of this round.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.